IP Library Granted Patent US 8,277,813
Granted Patent B2
US 8,277,813 · App. 11/932,985 · Granted Oct 2, 2012

Identification and molecular characterisation of proteins, expressed in the

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,277,813
App. No.
11/932,985
Granted
Oct 2, 2012
Kind
B2
Abstract

The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the Ixodes ricinus arthropod tick, during the slow-feeding phase of the blood meal have. The polynucleotide and related polypeptide may be used in different constructions and for different applications which are also included in the present invention.

Claims (9)

1. An isolated polypeptide consisting of the polypeptide sequence of SEQ ID NO: 36.

2. An isolated polypeptide consisting of the polypeptide sequence of SEQ ID NO: 36, wherein at least one amino acid in SEQ ID NO: 36 has asubstitution group, preferably selected from the group consisting of amide, acetyl, phosphoryl, and/or glycosyl groups.

3. An isolated fusion protein comprising a polypeptide consisting of the polypeptide sequence of SEQ ID NO: 36 fused to a heterologous polypeptide.

4. An isolated polypeptide comprising a polypeptide consisting of the polypeptide sequence of SEQ ID NO: 36 and at least one additional heterologous amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which help in purification or additional sequences for stability during recombination protection.

5. A pharmaceutical composition comprising an adequate pharmaceutical carrier and the polypeptide according to claim 1 .

6. The pharmaceutical composition according to claim 5 for the treatment of venous thrombosis, deep vein thrombosis, arterial thrombosis, cerebral ischemia, or pulmonary embolism.

7. An immunological composition for inducing antibody production or a T-cell immunological response to a tick salivary gland polypeptide in a mammalian host comprising the isolated polypeptide of claim 1 and optionally a carrier.

8. A diagnostic kit for detecting a disease induced or transmitted by tick, especially Ixodes ricinus , which comprises: the polypeptide of claim 1 .

9. The isolated polypeptide of claim 4 , wherein said sequences which help in purification comprise multiple histidine residues.

Assignments (5)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Feb 1, 2024
From: BIOXODES SA
To: BIOXODES SA
Reel/Frame 066431/0326 →
CHANGE OF NAME Recorded Aug 12, 2015
From: BIOXODES SPRL
To: BIOXODES SA
Reel/Frame 036309/0377 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2013
From: UNIVERSITE LIBRE DE BRUXELLES
To: BIOXODES SPRL
Reel/Frame 031271/0198 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2013
From: HENOGEN S.A.
To: L'UNIVERSITE LIBRE DE BRUXELLES
Reel/Frame 031282/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2008
From: GODFROID, EDMOND; DECREM, YVES; VANHAMME, LUC; BOLLEN, ALEX; LEBOULLE, GERARD
To: HENOGEN S.A.
Reel/Frame 020999/0350 →
Priority Claims (1)
GB GB9913425.6 · Jun 9, 1999 · national
Continuity (4)
Continuation In Part 10165605 · Jun 7, 2002
Continuation In Part 09910430 · Jul 19, 2001
Continuation In Part PCTBE0000061 · Jun 6, 2000
Related Publication 20080219970A1 · Sep 11, 2008